

**RECEIVED
CENTRAL FAX CENTER**

Serial No. 09/847,935
Reply of February 28, 2007

SEP 17 2007

D-2914

STATUS OF THE CLAIMS

Please enter the following claim set as a replacement for any previously presented claim set.

1-59. (Cancelled)

60. (Currently amended) A composition comprising:
an ion-pair complex including, in an aqueous medium, a therapeutic component comprising an adrenergic agonist, and an efficacy enhancing component, wherein the efficacy enhancing component comprises a fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, lignoceric acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and mixtures thereof, and is present in an amount greater than 0.2% (w/v) and less than about 10% (w/v), said amount being sufficient to complex substantially all of the therapeutic component in solution, wherein the ~~complex~~ composition comprises a 3:1, 2:1, 1:1, 1:2 or 1:3 molar ratio of efficiency-enhancing component to therapeutic component, and being effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

61. (Previously presented) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

Page 2 of 20.

Serial No. 09/847,935
Reply of February 28, 2007

D-2914

62. (Previously presented) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

63. (Previously presented) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

64. (Previously presented) The composition of claim 60 wherein the therapeutic component further comprises a second component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

65. (Previously presented) A composition of claim 60 which has a pH of about 7 or greater.

66. (Previously presented) A composition of claim 60 which has a pH in a range of about 7 to about 9.

67. (Cancelled)

Serial No. 09/847,935
Reply of February 28, 2007

D-2914

68. (Previously presented) A composition of claim 60 which is ophthalmically acceptable.

69-71 (Cancelled)

72. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of (2-imidazolyl-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

73. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

74-76. (Cancelled)

77. (Previously presented) The composition of claim 73, further comprising at least one additional efficacy enhancing component selected from the group consisting saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

78-86. (Cancelled)

87. (Currently amended) A composition comprising:
an ion-pair complex including, in an aqueous medium, a therapeutic component and an efficacy enhancing component other than a cyclodextrin or derivative thereof, wherein the complex

Serial No. 09/847,935
Reply of February 28, 2007

D-2914

composition comprises a 3:1, 2:1, 1:1, 1:2 or 1:3 molar ratio of efficiency-enhancing component to therapeutic component, wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, wherein the efficient enhancing component is present in an amount sufficient to complex substantially all of the therapeutic component in solution, and is effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of said the enhanced effects being relative to the effect obtained with the therapeutic component without complexed efficacy enhancing component.

88. (Previously presented) A composition of claim 87 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

89. (Previously presented) The composition of claim 87, wherein the therapeutic component is selected from the group consisting of (2-imidozolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

90. (Previously presented) The composition of claim 89, wherein the quinoxaline is selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.